JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

A

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

A

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

A

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

A

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

JNJ

225.79

-0.79%↓

ABT

93.07

+2.04%↑

MDT

83.21

-0.2%↓

A

115.95

+0.47%↑

VEEV

162.07

+0.76%↑

Search

Twist Bioscience Corp

Open

SectorHealthcare

59.97 -1.48

Overview

Share price change

24h

Current

Min

59.65

Max

61.56

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-10.08% downside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

1.2B

3.8B

Previous open

61.45

Previous close

59.97

News Sentiment

By Acuity

50%

50%

141 / 348 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

26 Apr 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26 Apr 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank -2-

24 Apr 2026, 19:19 UTC

Acquisitions, Mergers, Takeovers

Intertek Group Rejects EQT's Revised Offer

26 Apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26 Apr 2026, 23:44 UTC

Earnings

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26 Apr 2026, 23:44 UTC

Earnings

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26 Apr 2026, 23:36 UTC

Market Talk
Major News Events

Gold Falls Amid Dollar's Strength -- Market Talk

26 Apr 2026, 23:33 UTC

Market Talk
Major News Events

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26 Apr 2026, 05:12 UTC

Earnings

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26 Apr 2026, 05:12 UTC

Earnings

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26 Apr 2026, 05:12 UTC

Earnings

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26 Apr 2026, 05:12 UTC

Earnings

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24 Apr 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Scoring the Cook Era -- Barrons.com

24 Apr 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 Apr 2026, 20:50 UTC

Market Talk
Major News Events

Financial Services Roundup: Market Talk

24 Apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 Apr 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 Apr 2026, 20:09 UTC

Earnings

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 Apr 2026, 19:48 UTC

Market Talk
Major News Events

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 Apr 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 Apr 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 Apr 2026, 19:22 UTC

Earnings

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 Apr 2026, 19:06 UTC

Earnings

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 Apr 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 Apr 2026, 18:30 UTC

Acquisitions, Mergers, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 Apr 2026, 18:28 UTC

Acquisitions, Mergers, Takeovers

Intertek Rejects Revised EQT Offer

24 Apr 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 Apr 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 Apr 2026, 17:42 UTC

Earnings

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 Apr 2026, 17:28 UTC

Earnings

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

-10.08% downside

12 Months Forecast

Average 54.8 USD  -10.08%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

141 / 348 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat